DOW Agrees to Divest 50% Ownership in DowAksa Joint Venture
The sale proceeds are estimated to be $125 million, which will be used to support DOW's balanced capital allocation approach. This reflects an enterprise value of around 10x the estimated 2025 operating EBITDA.
The sale of the stake in the joint venture created in 2012 is expected to close in the third quarter of 2025. DOW's decision to exit is rooted in its best-owner mindset strategy of focusing on its core, high-value downstream businesses.
DOW stock has lost 47.1% over the past year compared with the industry's 24.9% decline.
Image Source: Zacks Investment Research
Dow, on its first-quarter call, said that it remains committed to disciplined execution and increased actions to boost profitability and support cash flow. It continues to take actions to address heightened macroeconomic and geopolitical uncertainties. Dow has delayed the construction of the Fort Saskatchewan Path2Zero project amid the prevailing market conditions.
Also, it is expanding the earlier announced review of European assets, mainly in polyurethanes, to address the challenging demand conditions and regulatory environment in the region. These new and earlier announced actions are expected to deliver roughly $6 billion in cash support.
DOW currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the Basic Materials space are Akzo Nobel N.V. AKZOY, Newmont Corporation NEM and Balchem Corporation BCPC. While AKZOY and NEM currently sport a Zacks Rank #1 (Strong Buy) each, BCPC carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Akzo Nobel's current-year earnings is pegged at $1.64 per share, implying a 17.14% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing once.
The Zacks Consensus Estimate for NEM's current-year earnings is pegged at $3.92 per share, indicating a 12.64% year-over-year rise.Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 32.41%. NEM's shares have gained 40.1% in the past year.
The Zacks Consensus Estimate for BCPC's 2025 earnings is pegged at $5.15 per share, indicating a rise of 31% from year-ago levels. The company's earnings beat the consensus estimate in two of the trailing four quarters while missing the rest. Its shares have gained 8.8% in the past year.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Dow Inc. (DOW) : Free Stock Analysis Report
Newmont Corporation (NEM) : Free Stock Analysis Report
Akzo Nobel NV (AKZOY) : Free Stock Analysis Report
Balchem Corporation (BCPC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
6 minutes ago
- Politico
Lindsey Graham's strategy for an end to Russia's war in Ukraine: Peace by pocketbook
Trump in early August hiked tariffs on India to 50 percent due to the country's purchasing of Russian oil. Graham claimed that it was those sanctions that drove Putin to acquiesce to the Alaska visit. And going after China — another major consumer of Russian oil — could prove even more pivotal, he said. 'If we take it to the next level and tell China you're next, then I think we can have an end to this war,' Graham said. 'The second most important person on the planet to end this war is President Xi in China. If he went to Putin and said it's time to end this war, I can't help you anymore because you're putting my country at threat, this war would end.' But Trump was far from threatening in his meeting with Putin last week. He rolled out the red carpet for the Russian leader and the two rode together in the presidential limousine. The meeting ended without a ceasefire or even concrete plans for a trilateral talk involving Ukrainian President Volodymyr Zelenskyy. But Graham was quick to attack those who suggested that meant the confab was a failure. Also on Sunday, special envoy Steve Witkoff said that Russia had consented to 'Article 5-like protections' for Ukraine at the conclusion of the war. 'To all these media analysts who say this was a bust, that's ridiculous,' he said. 'We have progress we didn't have before. We have momentum for peace. We'll see where it goes. So I'll leave it up to Trump.' Zelenskyy — and a selection of European leaders — will journey to Washington on Monday to touch base with Trump on what comes next. Graham insisted that Europe, too, must be willing to further sanction Russia in a bid to stop the fighting. 'To our European allies, up your game. Quit complaining about what we're not doing in America and do more yourself,' he said. 'Put tariffs on every country that buys Russian oil and gas cheaply to benefit Putin's war machine. Do what Trump's doing.'
Yahoo
34 minutes ago
- Yahoo
Tempus AI (TEM) Raises Full-Year Revenue Guidance
Tempus AI has posted an impressive price move of 21% over the last week, likely influenced by a blend of recent developments. The company announced significant revenue growth in its second quarter results and notably reduced its net loss. This positive financial performance was reinforced by the raised full-year revenue guidance, although it accompanies challenges such as a class action lawsuit and a substantial equity offering. The broader market has also been on an upward trajectory, with the Dow reaching records, which may have contributed to buoying Tempus AI's stock amidst mixed news on legal and financial fronts. We've discovered 3 warning signs for Tempus AI that you should be aware of before investing here. We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Tempus AI's recent developments, including significant revenue growth and reduced net loss for the second quarter, have influenced its impressive 21% share price increase over the last week. Over the longer period of the past year, the company's total return was 45.01%, showcasing substantial growth compared to both the broader market and its industry peers. Tempus AI outpaced the US Life Sciences industry, which had a return of -19.8%, and also exceeded the US market's 17% return. These positive financial results reinforce the company's revenue and earnings forecasts, supported by strong testing volumes and strategic biopharma partnerships. Analysts have projected Tempus AI's revenue to grow by 29.8% annually over the next three years, even though profitability remains elusive in the short term. The raised full-year revenue guidance could further bolster future earnings, provided reimbursement and regulatory challenges are effectively managed. Despite the current share price of $73.78, slightly above the consensus analyst price target of $70.0, the company's rapid growth trajectory potentially justifies this premium. Analysts' expectations reflect a degree of agreement regarding Tempus AI's valuation, suggesting that the stock may be fairly priced. However, sustained momentum in revenue, coupled with disciplined cost management, will be crucial for aligning with long-term growth objectives and closing any gaps between market performance and valuation targets. Our comprehensive valuation report raises the possibility that Tempus AI is priced higher than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TEM. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Here's Why Accenture (ACN) is a Strong Value Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. Why Investors Should Pay Attention to This Value Stock Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks. Accenture (ACN) Years of investment in digital, cloud and security strategy has helped Accenture evolve as a trusted and viable consulting services provider. It is currently one of the top consultancy firms of the world by revenues that increased 1.2% in fiscal 2024. ACN is a Zacks Rank #3 (Hold) stock, with a Value Style Score of B and VGM Score of A. Shares are currently trading at a forward P/E of 18.6X for the current fiscal year compared to the Computers - IT Services industry's P/E 17X. Additionally, ACN has a PEG Ratio of 2.2 and a Price/Cash Flow ratio of 15.4X. Value investors should also note ACN's Price/Sales ratio of 2.2X. Many value investors pay close attention to a company's earnings as well. For ACN, eight analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.19 to $12.88 per share for 2025. ACN boasts an average earnings surprise of 3%. ACN should be on investors' short list because of its impressive earnings and valuation fundamentals, a good Zacks Rank, and strong Value and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Accenture PLC (ACN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
